Agios to take over Alnylam’s preclinical siRNA blood disorder asset in a deal worth $147.5M

Paul Schloesser

Associate Editor

Agios and Alnylam have agreed on an exclusive global licensing deal worth $147.5 million for Agios to take over the development and commercialization of a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Agios to take over Alnylam’s preclinical siRNA blood disorder asset in a deal worth $147.5M

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Novo declares Phase 3 cardiac outcomes trial win for oral GLP-1

Starboard takes activist stake in J&J consumer spinout Kenvue

Former Karuna crew quickly assembles $225M for next neuro bet at Seaport

Q3 biotech roundup: The 2024 turnaround sputters into a critical Q4 finale

AstraZeneca-backed CDMO Nucleus RadioPharma to boost commercial capacity

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Agios to take over Al­ny­lam’s pre­clin­i­cal siR­NA blood dis­or­der as­set in a deal worth $147.5M

Associate Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Agios to take over Alnylam’s preclinical siRNA blood disorder asset in a deal worth $147.5M